Suggested remit: To appraise the clinical and cost effectiveness of dabrafenib with trametinib within its marketing authorisation for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5104

Provisional Schedule

Committee meeting: 1 12 March 2024
Expected publication 29 May 2024

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Novartis
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups The Brain Tumour Charity
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
08 August 2023 Invitation to participate
06 July 2023 (10:00) Scoping workshop
15 May 2023 - 13 June 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5104
07 July 2022 In progress. DHSC referral received
30 March 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual